Why is Kilitch Drugs falling/rising?

As of 22-Sep, Kilitch Drugs (India) Ltd is experiencing a decline in its stock price, currently at 352.50, which reflects a decrease of 3.05 points or 0.86%. The stock has been on a downward trend, having fallen for the last three consecutive days, resulting in a total decline of 3.12% during this period. Additionally, Kilitch Drugs is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment. Despite a healthy long-term growth trajectory with net sales increasing at an annual rate of 31.41% and operating profit at 72.48%, the company's recent performance has been marred by poor management efficiency, as evidenced by a low return on equity (ROE) of 7.27%. Furthermore, the stock's performance over the past year shows a decline of 4.78%, despite profits rising significantly by 122.7%, which may suggest a disconnect between profitability and stock performance.
In the broader market context, Kilitch Drugs' short-term performance has lagged behind the benchmark, with a 1-week return of 0.14% compared to the Sensex's 0.46%. This underperformance may be contributing to investor sentiment, as domestic mutual funds hold no stake in the company, potentially indicating a lack of confidence in its valuation or business prospects. The stock's liquidity appears adequate, with a delivery volume increase of 58.83% against the 5-day average, but the overall market perception remains cautious. The combination of declining stock price, poor management efficiency, and limited institutional interest suggests that investors are wary, leading to the current downward movement in Kilitch Drugs' stock price.